PHARMACEUTICAL CONTRACT MANUFACTURING - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in US$ Thousand by the following Dosage Forms: Injectables (Injections, Vials, and IV solutions), Solid Dosage Forms (Tablets and Capsules), and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 92 companies including many key and niche players such as -

AAIPharma Services Corporation
Aenova Group
Ajinomoto Althea, Inc.
Albany Molecular Research, Inc.
Dishman


Click here to request a full list of companies covered in the report...

Code: MCP-1535
Price: $4950
Companies: 92
Pages: 185
Date: June 2014
Market Data Tables: 39
Status: * New Report

Complimentary Market Brief:


Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS


 
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   A Curtain Raiser.....II-11$100
   Cost and Risk Containment Objectives Spur Outsourcing of Biopharma Production.....II-2
Key Market Drivers.....II-2
1$100
   Biopharma Contract Manufacturing Market Emerges from the Recessionary Lull.....II-3
Table 1: Worldwide Funding for Biotech Projects by Geographic Region (2012): Percentage Breakdown of Funding for North America, Europe, and Rest of World (includes corresponding Graph/Chart).....II-3
1$350
   Table 2: Worldwide Funding for Biotech Projects by Product Development Phase (2012): Percentage Breakdown of Funding for Products in Clinical Trial, Pre-Clinical Trial and Commercialization Phases (includes corresponding Graph/Chart).....II-4
Favorable Trends in the Pharma Industry Portend Bright Outlook for the PCM
  Market.....II-4
Ballooning Global Population Offers Increased Growth Opportunities.....II-4
1$350
   Table 3: Top 25 Countries Worldwide in Terms of Population: 2007, 2010 & 2013.....II-5
Surge in Generic Drugs to Benefit Pharmaceutical Contract Manufacturers.....II-5
1$350
   Table 4: Worldwide Annual Spending on Drugs by Category (2011 & 2015): Percentage Breakdown of Dollar Sales for Branded Drugs, Generic Drugs, and Others (includes corresponding Graph/Chart).....II-6
Increasing Consumption Drugs within Aging Population Boosts Opportunities for
  PCM.....II-6
1$350
   Table 5: Global Population Statistics for the 65+ Age Group (2012) (includes corresponding Graph/Chart).....II-71$350
   Table 6: Elderly Population (65+ Years) as a % of Total Population (2025) (includes corresponding Graph/Chart).....II-8
Changing Healthcare Expenditure Trends to Spur Demand for Contract Manufacturing of
  Generics.....II-8
2$350
   Table 7: Healthcare Spending as a Percentage of GDP: 2012 (includes corresponding Graph/Chart).....II-10
US and Europe Dominate Market, Asia-Pacific Lends Growth Momentum.....II-10
1$350
   Major Changes Imperative to Capitalize on Brighter Future Prospects.....II-11
Solid Dosage Form Retains Popularity among Pharma Contract Manufacturers.....II-11
1$100
   Injectable-Dose Formulations to Spearhead Growth of the PCM Market.....II-122$200
   Patent Expiries Augur Good Tidings for the PCM Market.....II-14
PCMs Gear Up to Tap Booming Biologics Market.....II-14
PCM Market for Vaccines Yet to Take Off.....II-14
1$100
   Biotechnology Upstarts Spur Demand for Contract Manufacturing.....II-15
Vendor Switching- A Growing Concern for PCMs.....II-15
1$100
   Marked Decrease Witnessed in Venture Capital Investment into PCM Upstarts.....II-16
PCM Industry Gravitates Eastward, and Subsequently Leads to Near-Shoring.....II-16
1$100
   Adoption of Cutting-Edge Technologies to Radicalize PCM Environment.....II-17
RABS technology.....II-17
1$100
   Quality by Design.....II-18
Track & Trace Techniques.....II-18
Disposable Processing Techniques.....II-18
Upstream & Downstream Processes.....II-18
1$100
   Process Analytical Technology.....II-19
Near Infrared Spectroscopy.....II-19
Increased Regulator Scrutiny: A Cause of Concern for the Emerging Market PCMs.....II-19
1$100
   PCM – A Highly Fragmented Industry Undergoing Consolidation.....II-20
Table 8: Worldwide Pharmaceutical Contract Manufacturing Market by Leading Players (2013): Percentage Breakdown of Value Sales for Catalent Pharma Solutions, DPx Holdings B.V., Famar Health Care Services, and Others (includes corresponding Graph/Chart).....II-20

Table 9: Worldwide Injectables Contract Manufacturing Market by Leading Players (2013): Percentage Breakdown of Value Sales for Baxter, Hospira, Vetter and Others (includes corresponding Graph/Chart).....II-20
PCMs Battle Fierce Competition and Commoditization.....II-20
1$350
   Large Enterprises Edging Out Small-scale Players.....II-21
Competitive Pricing Pressure to Spur Consolidation.....II-21
1$100
   Competition Heats Up in Injectables Market, PCMs Expand Capabilities and Service
  Offerings.....II-22
1$100
   Introduction.....II-23
Injectables (Injections, Vials, and IV solutions).....II-23
Solid Dosage Forms (SDFs) (Tablets and Capsules).....II-23
1$100
   Liquid Dosage Forms (LDFs) (Syrups and Suspensions).....II-24
An Insight into the Rise of Pharmaceutical Contract Manufacturing.....II-24
1$100
   Investment Risks in Pharmaceutical Contract Manufacturing.....II-25
Quality Assurance Risk.....II-25
Drug Development Risk.....II-25
Acquisition Risk.....II-25
Client Dependency Risk.....II-25
1$100
   Onyx Announces completion of API project with Neuronascent.....II-26
Meiji Holdings Buys Medreich Lifecare Limited.....II-26
Emilia Group Takes Over Pharma Pac LLC.....II-26
AMRI to Take Over Cedarburg Pharma.....II-26
AMRI to Acquire OsoBio Biopharmaceuticals Manufacturing.....II-26
Royal DSM’s DPP Merges with JLL Partners’ Pantheon, Giving Rise to DPx Holdings
  B.V......II-26
Emergent BioSolutions Takes Over Cangene Corporation.....II-26
1$100
   Dendreon Appoints PharmaCell as European CMO.....II-27
Ajinomoto Acquires Althea Technologies.....II-27
Aenova Group Merges with Haupt Pharma.....II-27
Kemwell Biopharma Takes Over Cirrus Pharmaceuticals.....II-27
Questcor Acquires BioVectra.....II-27
ICON Buys Cross Country Healthcare’s Clinical Trial Services Division.....II-27
Columbia Laboratories Acquires Molecular Profiles.....II-27
EPS Corp Acquires Gleneagles CRC from IHH Healthcare.....II-27
1$100
   Capsugel to Take Over Bend Research.....II-28
Gallus BioPharmaceutical Takes Over Laureate Biopharmaceutical.....II-28
PLI Holdings Acquires Pfanstiehl Laboratories.....II-28
DPT Laboratories Announce Integration With Confab.....II-28
Nordion Inks Contract Manufacturing Agreement with Navidea.....II-28
Unilife Receives Injectables Contract from Hikma.....II-28
NextPharma Technologies Expands Bielefeld Production Capacity and Capabilities.....II-28
Fuji Pharma to Acquire OLIC from DKSH.....II-28
DSM Pharmaceutical Partners Almac Group.....II-28
1$100
   Metrics Inc Introduces Generic Drug of Oxycodone HCl 5mg.....II-29
Patheon Completes Acquires Banner Pharmacaps.....II-29
PAREXEL International Acquires Liquent.....II-29
American Capital Acquires Cambridge Major.....II-29
Aenova Group Takes Over Euro Vital Pharma.....II-29
Althea Technologies Receives Contract from Pfenex.....II-29
1$100
   AAIPharma Services Corporation (US).....II-30
Aenova Group (Germany).....II-30
Haupt Pharma AG (Germany).....II-30
1$100
   Ajinomoto Althea, Inc. (US).....II-31
Albany Molecular Research Inc. (US).....II-31
1$100
   Boehringer Ingelheim GmbH (Germany).....II-32
Catalent Pharma Solutions, Inc. (US).....II-32
1$100
   Dishman (India).....II-33
DPx Holdings B.V. (US).....II-33
1$100
   Famar Health Care Services (Greece).....II-34
Hospira, Inc. (US).....II-34
Jubilant Life Sciences Limited (India).....II-34
1$100
   Kemwell Biopharma Pvt. Ltd (India).....II-35
Lonza Group Ltd. (Switzerland).....II-35
1$100
   NextPharma Technologies Holding Ltd (UK).....II-36
Nipro Pharma Corporation (Japan).....II-36
1$100
   Recipharm AB (Sweden).....II-37
Cobra Biologics Holding AB (Sweden).....II-37
1$100
   Table 10: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart).....II-381$350
   Table 11: World Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart).....II-391$350
   Table 12: World 15-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....II-401$350
   Table 13: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart).....II-411$350
   Table 14: World Historic Review for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart).....II-421$350
   Table 15: World 15-Year Perspective for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....II-431$350
   Table 16: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart).....II-441$350
   Table 17: World Historic Review for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart).....II-451$350
   Table 18: World 15-Year Perspective for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....II-461$350
   Table 19: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart).....II-471$350
   Table 20: World Historic Review for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart).....II-481$350
   Table 21: World 15-Year Perspective for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....II-491$350
   A. Market Analysis.....III-1
US PCM Market Overview.....III-1
1$75
   Competitive Landscape.....III-2
Strategic Corporate Developments.....III-2
2$150
   Select Key Players.....III-43$225
   B. Market Analytics.....III-7
Table 22: The US Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart).....III-7
1$200
   Table 23: The US Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart).....III-81$200
   Table 24: The US 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-91$200
   A. Market Analysis.....III-10
Strategic Corporate Developments.....III-10
1$75
   B. Market Analytics.....III-11
Table 25: Canadian Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart).....III-11
1$200
   Table 26: Canadian Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart).....III-121$200
   Table 27: Canadian 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-131$200
   A. Market Analysis.....III-14
Strategic Corporate Development.....III-14
Nipro Pharma Corporation – A Key Japanese Player.....III-14
1$75
   B. Market Analytics.....III-15
Table 28: Japanese Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart).....III-15
1$200
   Table 29: Japanese Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart).....III-161$200
   Table 30: Japanese 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-171$200
   A. Market Analysis.....III-18
European PCM Market Caught in Eurodebt Doldrums.....III-18
Injectables Segment Offers Promising Potential.....III-18
1$75
   Mammalian Cell Technology Dominates PCM Market.....III-19
Competitive Scenario.....III-19
Overview of Select Markets.....III-19
Germany.....III-19
Russia.....III-19
1$75
   Strategic Corporate Developments.....III-201$75
   Select Key Players.....III-213$225
   B. Market Analytics.....III-24
Table 31: European Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart).....III-24
1$200
   Table 32: European Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart).....III-251$200
   Table 33: European 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-261$200
   A. Market Analysis.....III-27
Favorable Government Policies Transform China and India into PCM Hubs.....III-27
Competitive Scenario.....III-27
1$75
   Overview of Select Regional Markets.....III-28
China.....III-28
Outsourcing Industry Bogged Down by Recession.....III-28
India.....III-28
1$75
   Indian PCMs Battle Soaring Costs.....III-29
Strategic Corporate Developments.....III-29
Select Key Players.....III-29
2$150
   B. Market Analytics.....III-31
Table 34: Asia-Pacific Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart).....III-31
1$200
   Table 35: Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart).....III-321$200
   Table 36: Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-331$200
   Market Analysis.....III-34
Table 37: Rest of World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart).....III-34
1$200
   Table 38: Rest of World Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart).....III-351$200
   Table 39: Rest of World 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-361$200
  
Total Companies Profiled: 92 

Region/Country Players

The United States 34 Canada 3 Japan 4 Europe 33 France 3 Germany 8 The United Kingdom 9 Italy 3 Rest of Europe 10 Asia-Pacific (Excluding Japan) 18
Click here to request a full table of contents and more details on this project.